OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

被引：0
|
作者：
Van Laethem, Jean-Luc
Borbath, Ivan
Geboes, Karen Paula
Cassier, Philippe Alexandre
Lambert, Aurelien
Mitry, Emmanuel
Prenen, Hans
Pilla, Lorenzo
Blanc, Jean-Frederic
Gallego Jimenez, Inmaculada
Cid, Roberto A. Pazo
Rodriguez Garrote, Mercedes
Feliu, Jaime
Nordbladh, Karin
Smith, Karin Enell
Gomez Jimenez, David
Ellmark, Peter
Pico de Coa, Yago
Ambarkhane, Sumeet Vijay
Macarulla, Teresa
机构：
[1] Erasme Univ Hosp, Brussels, Belgium
[2] St Luc Univ Clin, Brussels, Belgium
[3] Ghent Univ Hosp, Div Digest Oncol, Dept Gastroenterol, Ghent, Belgium
[4] Ctr Leon Berard, Lyon, France
[5] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[6] Inst Paoli Calmettes, Marseille, France
[7] Univ Hosp Gasthuisberg, Leuven, Belgium
[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Gastroenterol & Gastrointestinal Oncol, Paris, France
[9] Hop Haut Leveque, Pessac, France
[10] Hosp Univ Virgen Rocio, Seville, Spain
[11] Hosp Univ Miguel Servet, Zaragoza, Spain
[12] Hosp Univ Ramon y Cajal, Madrid, Spain
[13] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[14] Alligator Biosci AB, Lund, Sweden
[15] Vall Hebron Univ Hosp, Barcelona, Spain
[16] Vall Hebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4133
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study
    Van Laethem, Jean-Luc
    Geboes, Karen P.
    Cassier, Philippe A.
    Borbath, Ivan
    Lambert, Aurelien
    Mitry, Emmanuel
    Prenen, Hans
    Blanc, Jean-Frederic
    Pilla, Lorenzo
    Garrote, Mercedes Rodriguez
    Cid, Roberto A. Pazo
    Gallego, Inmaculada
    Feliu, Jaime
    Nordbladh, Karin
    Ellmark, Peter
    Carlsson, Malin
    de Coana, Yago Pico
    Ambarkhane, Sumeet V.
    Macarulla, Teresa
    CANCER RESEARCH, 2024, 84 (02)
  • [2] Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre, phase 1b/2 study
    Van Laethem, Jean -Luc
    Borbath, Ivan
    Prenen, Hans
    Geboes, Karen Paula
    Lambert, Aurelien
    Mitry, Emmanuel
    Cassier, Philippe Alexandre
    Blanc, Jean-Frederic
    Pilla, Lorenzo
    Batlle, Jaime Feliu
    Garrote, Mercedes Rodriguez
    Pazo-Cid, Roberto Antonio
    Gallego, Inmaculada
    Smith, Karin Enell
    Ellmark, Peter
    de Coana, Yago Pico
    Ambarkhane, Sumeet Vijay
    Macarulla, Teresa
    LANCET ONCOLOGY, 2024, 25 (07): : 853 - 864
  • [3] Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study
    Prenen, Hans
    Borbath, Ivan
    Paula Geboes, Karen
    Alexandre Cassier, Philippe
    Lambert, Aurelien
    Mitry, Emmanuel
    Macarulla, Teresa
    Taieb, Julien
    Blanc, Jean-Frederic
    Feliu Batlle, Jaime
    Rodriguez Garrote, Mercedes
    Pazo Cid, Roberto A.
    Valladares-Ayerbes, Manuel
    Nordbladh, Karin
    Enell Smith, Karin
    Ellmark, Peter
    Carlsson, Malin
    Pico de Coana, Yago
    Vijay Ambarkhane, Sumeet
    Van Laethem, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
    Macarulla Mercade, T.
    Borbath, I.
    Geboes, K.
    Lambert, A.
    Cassier, P.
    Prenen, H.
    Mitry, E.
    Blanc, J. F.
    Pilla, L.
    Feliu, J.
    Rodriguez, M.
    Cid, R. A. Pazo
    Gallego Jimenez, I.
    Gomez Jimenez, D.
    Smith, K. E.
    Nordbladh, K.
    Ellmark, P.
    Pico de Coana, Y.
    Ambarkhane, S. V.
    van Laethem, J-L.
    ANNALS OF ONCOLOGY, 2024, 35 : S118 - S118
  • [5] Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Prenen, Hans
    Lambert, Aurelien
    Geboes, Karen
    Blanc, Jean-Frederic
    de Coana, Yago Pico
    Enell-Smith, Karin
    Schultz, Lena
    Nordbladh, Karin
    Ellmark, Peter
    Ambarkhane, Sumeet
    Carlsson, Malin
    Cassier, Philippe
    CANCER RESEARCH, 2022, 82 (22) : 10 - 11
  • [6] OPTIMIZE-1, AN OPEN-LABEL PHASE 1B/2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAZALIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    de Coana, Yago Pico
    Smith, Karin Enell
    Falt, Anette
    Flardh, Maria
    Ellmark, Peter
    Cassier, Philippe
    van Laethem, Jean-Luc
    Carlsson, Malin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A567 - A567
  • [7] Mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (PDAC): Safety data from part of the OPTIMIZE-1 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Prenen, Hans
    de Coana, Yago Pico
    Smith, Karin Enell
    Nordbladh, Karin
    Ellmark, Peter
    Ambarkhane, Sumeet Vijay
    Carlsson, Malin
    Cassier, Philippe Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16237 - E16237
  • [8] Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs).
    O'Reilly, Eileen M.
    Macarulla, Teresa
    Dahan, Laetitia
    Borbath, Ivan
    Cassier, Philippe Alexandre
    Guelfucci, Florent
    Ngami, Armel
    Pico de Coana, Yago
    Wainberg, Zev A.
    Ambarkhane, Sumeet Vijay
    Van Laethem, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 723 - 723
  • [9] CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) in the OPTIMIZE-1 study.
    Wattenberg, Max Miller
    Smith, Karin Enell
    de Coana, Yago Pico
    Jimenez, David Gomez
    Ambarkhane, Sumeet Vijay
    Ellmark, Peter
    Beatty, Gregory Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study
    Coveler, Andrew L.
    Reilley, Matthew
    Zalupski, Mark
    Macarulla, Teresa
    Fountzilas, Christos
    Castanon Alvarez, Eduardo
    Nagrial, Adnan
    Volodymyrivna Uboha, Nataliya
    Frentzas, Sophia
    Overman, Michael J.
    Noonan, Anne M.
    Messersmith, Wells A.
    Pavlakis, Nick
    Mettu, Niharika B.
    Smith, Paul
    Murtomaki, Elina
    Bragulat, Veronique
    Cooper, Zachary A.
    Kumar, Rakesh
    Spigel, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345